ES2776179T3 - Anticuerpos dirigidos contra determinantes de la superficie de S. aureus - Google Patents
Anticuerpos dirigidos contra determinantes de la superficie de S. aureus Download PDFInfo
- Publication number
- ES2776179T3 ES2776179T3 ES13852597T ES13852597T ES2776179T3 ES 2776179 T3 ES2776179 T3 ES 2776179T3 ES 13852597 T ES13852597 T ES 13852597T ES 13852597 T ES13852597 T ES 13852597T ES 2776179 T3 ES2776179 T3 ES 2776179T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- amino acid
- acid sequence
- aureus
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 12
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 3
- 101710197219 Alpha-toxin Proteins 0.000 abstract 3
- 101710124951 Phospholipase C Proteins 0.000 abstract 3
- 239000002776 alpha toxin Substances 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una composición que comprende (i) un anticuerpo monoclonal humano aislado o un fragmento de unión a antígeno del mismo que se unen específicamente a una alfa toxina (AT) de S. aureus y (ii) un anticuerpo monoclonal humano aislado o un fragmento de unión a antígeno del mismo que se unen específicamente al determinante antigénico IsdH de la superficie de S. aureus, en donde el anticuerpo aislado o el fragmento de unión a antígeno del mismo que se unen específicamente a AT comprenden: a. una CDR1 de VH que comprende una secuencia de aminoácidos de SEQ ID NO: 69; b. una CDR2 de VH que comprende una secuencia de aminoácidos de SEQ ID NO: 70; c. una CDR3 de VH que comprende una secuencia de aminoácidos de SEQ ID NO: 71; d. una CDR1 de VL que comprende una secuencia de aminoácidos de SEQ ID NO: 1; e. una CDR2 de VL que comprende una secuencia de aminoácidos de SEQ ID NO: 2; y f. una CDR3 de VL que comprende una secuencia de aminoácidos de SEQ ID NO: 68; en donde el anticuerpo aislado o el fragmento de unión a antígeno del mismo que se unen específicamente a IsdH comprenden a. una CDR1 de VH que tiene la secuencia de aminoácidos de SEQ ID NO: 90; b. una CDR2 de VH que tiene la secuencia de aminoácidos de SEQ ID NO: 91; c. una CDR3 de VH que tiene la secuencia de aminoácidos de SEQ ID NO: 92; d. una CDR1 de VL que tiene la secuencia de aminoácidos de SEQ ID NO: 93; e. una CDR2 de VL que tiene la secuencia de aminoácidos de SEQ ID NO: 94; y f. una CDR3 de VL que tiene la secuencia de aminoácidos de SEQ ID NO: 95.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723137P | 2012-11-06 | 2012-11-06 | |
| US201361782405P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/068624 WO2014074540A2 (en) | 2012-11-06 | 2013-11-06 | Antibodies to s. aureus surface determinants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2776179T3 true ES2776179T3 (es) | 2020-07-29 |
Family
ID=50685304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13852597T Active ES2776179T3 (es) | 2012-11-06 | 2013-11-06 | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9879070B2 (es) |
| EP (2) | EP3640338A1 (es) |
| JP (2) | JP6694269B2 (es) |
| KR (1) | KR102288394B1 (es) |
| CN (2) | CN109553681A (es) |
| AU (2) | AU2013341361A1 (es) |
| BR (1) | BR112015010125A2 (es) |
| CA (1) | CA2890427C (es) |
| DK (1) | DK2917360T3 (es) |
| ES (1) | ES2776179T3 (es) |
| HU (1) | HUE049012T2 (es) |
| MX (2) | MX375324B (es) |
| PL (1) | PL2917360T3 (es) |
| RU (1) | RU2698131C2 (es) |
| SG (2) | SG10201703678TA (es) |
| WO (1) | WO2014074540A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527905B2 (en) * | 2011-02-08 | 2016-12-27 | Medimmune, Llc | Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use |
| HRP20180458T1 (hr) | 2011-06-10 | 2018-06-29 | Medimmune Limited | Molekule koje vežu anti-pseudomonas psl i njihova uporaba |
| AU2012336028A1 (en) * | 2011-11-07 | 2014-06-26 | Medimmune, Llc | Combination therapies using anti- Pseudomonas Psl and PcrV binding molecules |
| WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
| US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| RU2661406C2 (ru) | 2012-11-06 | 2018-07-16 | МЕДИММЬЮН, ЭлЭлСи | Способы лечения заболеваний, ассоциированных с s. aureus |
| ES2776179T3 (es) | 2012-11-06 | 2020-07-29 | Medimmune Llc | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus |
| EP3154584B1 (en) * | 2014-06-03 | 2021-08-04 | XBiotech Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| AU2015303147A1 (en) * | 2014-08-12 | 2017-02-23 | Arsanis Biosciences Gmbh | Predicting S. aureus disease |
| WO2016073860A1 (en) * | 2014-11-06 | 2016-05-12 | Medimmune, Llc | Binding molecules specific for staphylococcus protein a and uses thereof |
| FR3033333A1 (fr) * | 2015-03-06 | 2016-09-09 | Commissariat Energie Atomique | Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations |
| US20180179267A1 (en) * | 2015-04-17 | 2018-06-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| WO2017075188A2 (en) * | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
| CN105424930A (zh) * | 2015-11-23 | 2016-03-23 | 天津科技大学 | 一种快速检测金黄色葡萄球菌的方法 |
| CA3076632A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
| WO2020023644A2 (en) * | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| AU2019359207A1 (en) | 2018-10-09 | 2021-05-20 | Humabs Biomed Sa | Antibodies directed against Staphylococcus aureus leukotoxins |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| EP3923978A1 (en) | 2019-02-12 | 2021-12-22 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| WO2020185986A1 (en) | 2019-03-13 | 2020-09-17 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
| WO2020210650A1 (en) | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| KR102397684B1 (ko) * | 2019-12-09 | 2022-05-13 | (주)옵토레인 | 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법 |
| KR102504175B1 (ko) * | 2020-06-17 | 2023-02-28 | (주)옵토레인 | 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법 |
| KR102674109B1 (ko) * | 2021-01-14 | 2024-06-12 | (주)옵토레인 | 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법 |
| KR102674098B1 (ko) * | 2021-01-14 | 2024-06-12 | (주)옵토레인 | 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법 |
| KR102674120B1 (ko) * | 2021-01-18 | 2024-06-12 | (주)옵토레인 | 스위칭 펩티드 및 이를 이용한 면역분석 방법 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2017198A (en) * | 1931-10-17 | 1935-10-15 | Anglada Motor Corp | Cuff valve engine |
| US20030044772A1 (en) | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| ES2372686T3 (es) * | 2001-01-26 | 2012-01-25 | Inhibitex, Inc. | Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones. |
| US7604799B2 (en) * | 2003-06-06 | 2009-10-20 | Medimmune, Llc | EphA4 Antibodies |
| WO2005019267A2 (en) | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US20080050361A1 (en) * | 2004-10-25 | 2008-02-28 | Heinrichs David E | Staphylococcus aureas specific anti-infectives |
| CA2638833A1 (en) * | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| EP2719397A1 (en) * | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| CA2667788A1 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| US9526774B1 (en) * | 2006-11-06 | 2016-12-27 | Microvax, Llc | Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus |
| PL2244722T3 (pl) * | 2008-01-31 | 2017-04-28 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin | Leczenie zakażeń drobnoustrojami |
| CN102089005A (zh) * | 2008-05-12 | 2011-06-08 | 斯特罗克斯生物制药有限责任公司 | 金黄色葡萄球菌特异性抗体制剂 |
| US8280643B2 (en) * | 2008-06-30 | 2012-10-02 | The Texas A & M University System | Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof |
| CA2739581A1 (en) * | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
| WO2011127032A1 (en) * | 2010-04-05 | 2011-10-13 | University Of Chicago | Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response |
| WO2011019423A2 (en) * | 2009-05-20 | 2011-02-17 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
| JP5395264B2 (ja) * | 2009-06-22 | 2014-01-22 | ワイス・エルエルシー | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物 |
| KR101832201B1 (ko) * | 2009-07-15 | 2018-02-28 | 에임 쎄라퓨틱스 비.브이. | 그람-양성 박테리아 특이적 결합 화합물 |
| GB0913680D0 (en) * | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| WO2011079308A2 (en) * | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| EP2614074A1 (en) * | 2010-09-09 | 2013-07-17 | The University of Chicago | Methods and compositions involving protective staphylococcal antigens |
| US20120202047A1 (en) | 2011-02-07 | 2012-08-09 | Baker Hughes Incorporated | Nano-coatings for articles |
| US9527905B2 (en) * | 2011-02-08 | 2016-12-27 | Medimmune, Llc | Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use |
| EP2744517B1 (en) * | 2011-08-15 | 2019-03-13 | The University of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
| PT2794905T (pt) * | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
| NZ702285A (en) * | 2012-04-26 | 2016-07-29 | Univ Chicago | Staphylococcal coagulase antigens and methods of their use |
| ES2776179T3 (es) * | 2012-11-06 | 2020-07-29 | Medimmune Llc | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus |
| RU2661406C2 (ru) * | 2012-11-06 | 2018-07-16 | МЕДИММЬЮН, ЭлЭлСи | Способы лечения заболеваний, ассоциированных с s. aureus |
| WO2014127200A1 (en) * | 2013-02-15 | 2014-08-21 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| US20160235832A1 (en) * | 2013-10-15 | 2016-08-18 | The Texas A&M University System | Compositions and the Use of Fibrinogen Binding Motif Presence in EFB and COA for Vaccine Against Staphylococcus Aureus and Drug Delivery |
| WO2015106226A2 (en) * | 2014-01-10 | 2015-07-16 | University Of Rochester | Diagnostic device and method for detection of staphylococcus infection |
| US9353189B2 (en) * | 2014-01-24 | 2016-05-31 | William R Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
| EP3154584B1 (en) * | 2014-06-03 | 2021-08-04 | XBiotech Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
| TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| WO2016073860A1 (en) * | 2014-11-06 | 2016-05-12 | Medimmune, Llc | Binding molecules specific for staphylococcus protein a and uses thereof |
| US20180179267A1 (en) | 2015-04-17 | 2018-06-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| WO2017075188A2 (en) * | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| US11344615B2 (en) * | 2016-07-08 | 2022-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells |
| WO2020023644A2 (en) * | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| CN113164602A (zh) * | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| AU2019359207A1 (en) * | 2018-10-09 | 2021-05-20 | Humabs Biomed Sa | Antibodies directed against Staphylococcus aureus leukotoxins |
| WO2020185986A1 (en) * | 2019-03-13 | 2020-09-17 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
-
2013
- 2013-11-06 ES ES13852597T patent/ES2776179T3/es active Active
- 2013-11-06 PL PL13852597T patent/PL2917360T3/pl unknown
- 2013-11-06 JP JP2015540879A patent/JP6694269B2/ja active Active
- 2013-11-06 KR KR1020157014912A patent/KR102288394B1/ko active Active
- 2013-11-06 EP EP19211610.1A patent/EP3640338A1/en active Pending
- 2013-11-06 WO PCT/US2013/068624 patent/WO2014074540A2/en not_active Ceased
- 2013-11-06 HU HUE13852597A patent/HUE049012T2/hu unknown
- 2013-11-06 CN CN201811621407.0A patent/CN109553681A/zh active Pending
- 2013-11-06 DK DK13852597.7T patent/DK2917360T3/da active
- 2013-11-06 CN CN201380057603.9A patent/CN104968797B/zh active Active
- 2013-11-06 US US14/440,748 patent/US9879070B2/en active Active
- 2013-11-06 CA CA2890427A patent/CA2890427C/en active Active
- 2013-11-06 BR BR112015010125A patent/BR112015010125A2/pt not_active Application Discontinuation
- 2013-11-06 RU RU2015121624A patent/RU2698131C2/ru active
- 2013-11-06 EP EP13852597.7A patent/EP2917360B1/en active Active
- 2013-11-06 SG SG10201703678TA patent/SG10201703678TA/en unknown
- 2013-11-06 SG SG11201503232TA patent/SG11201503232TA/en unknown
- 2013-11-06 AU AU2013341361A patent/AU2013341361A1/en not_active Abandoned
- 2013-11-06 MX MX2015005477A patent/MX375324B/es active IP Right Grant
-
2015
- 2015-04-29 MX MX2022008079A patent/MX2022008079A/es unknown
-
2018
- 2018-01-25 US US15/880,157 patent/US10730934B2/en active Active
- 2018-10-04 AU AU2018241107A patent/AU2018241107B2/en active Active
-
2019
- 2019-01-25 JP JP2019011283A patent/JP2019089801A/ja not_active Withdrawn
-
2020
- 2020-07-09 US US16/925,129 patent/US11447543B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2013198490A5 (es) | ||
| NZ712765A (en) | Antibodies that bind csf1r | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| BR112018006579A2 (pt) | anticorpos anti-humanos cd19 humanizados e métodos de uso | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| ZA201806397B (en) | Humanized anti clever-1 antibodies and their use | |
| EA201892313A1 (ru) | Гуманизированные антитела против clever-1 и их применение | |
| AR096445A1 (es) | Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga | |
| BR112017003138A2 (pt) | anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno | |
| AR107083A1 (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
| AR106471A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| NZ620100A (en) | Rspo binding agents and uses thereof | |
| AR107883A1 (es) | Polipéptidos de unión a la proteína a, anticuerpos anti-epha2 y métodos de uso de éstos | |
| AR105800A1 (es) | Polipéptidos mrka, anticuerpos anti-mrka y sus usos | |
| NZ781203A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof |